GC-REAADTM is an in-vitro diagnostic intended for early detection of gastric carcinoma using a novel patent-pending biomarker. This biomarker was discovered to be expressed at high levels in the patient’s plasma samples. Additionally, risk factor for gastric cancer like Helicobacter pylori (H. pylori) infection, does not influence the biomarkers expression levels within plasma.

The competition between the patent pending biomarker and its specific antibodies is the gist of how GC-REAADTM functions. Positive or negative results obtained through calculations helps to determine the patients’ status of gastric cancer. 


About Gastric Carcinoma

Gastric Carcinoma, also known as stomach cancer, has one of the highest incidence rate and mortalities worldwide, especially in Asia(Globocan,2012). The total estimated new cases in 2012 amounted to 952,000, which is approximately 6.8% of total new cancer cases (International Agency for Research for Cancer). There are no associated symptoms for early gastric carcinoma, most of the symptoms appear only at late stages. Late diagnosis is one of the main reasons that reduces effective treatments and increases complications to treat gastric carcinoma. Costly and invasive conventional methods for early screening and diagnosis such as endoscopy often deter people to seek early screening.

Statistics (Globocan 2012)
Worldwide – 5th most common cancer; 3rd cause of cancer-related death
Europe – 6th most common cancer; 4th cause of cancer-related death
Asia – 2nd most common cancer; 3rd cause of cancer-related death